Drinking in moderation can help avoid ‘holiday heart syndrome’ – UT Southwestern

(Photo credit: Getty Images)

DALLAS Dec. 20, 2023 The holiday season is a time for celebration, but too much celebrating can be bad for your health.

December brings a notable bump in the number of patients who show up at hospital emergency rooms with whats known unofficially as holiday heart syndrome heart rhythm problems caused by excessive alcohol consumption, said Sharon Reimold, M.D., Professor and Vice Chair for Clinical Operations and Faculty Development in the Department of Internal Medicine at UT Southwestern Medical Center.

Sharon Reimold, M.D., Professor and Vice Chair for Clinical Operations and Faculty Development in the Department of Internal Medicine at UTSouthwestern, holds the Gail Griffiths Hill Chair in Cardiology.

Its common for people to go to multiple parties during this time of year. You go to one party and have a drink or two, go to the next party and have a couple more. Its the cumulative effect of alcohol that can put you at risk, sending your heart into atrial fibrillation, noted Dr. Reimold, who is a cardiologist.

Atrial fibrillation, or AFib, is an irregular and rapid contraction of the upper chambers of the heart. The most common symptoms include shortness of breath, lightheadedness, chest pain, heart palpitations, and a feeling that the heart is beating much faster than normal. AFib is associated with an increased risk of stroke and heart failure.

Symptoms may be sporadic and usually clear up within 24 hours, but you should never ignore them. Always seek medical assistance whenever you experience heart problems, including holiday heart syndrome.

The condition doesnt manifest only during the holidays. It can occur any time excess alcohol is involved. Too much food, particularly salty foods, can also be a contributing factor.

Federal health guidelines define moderate alcohol consumption as no more than two drinks a day for men and no more than one a day for women. A drink is defined as 8 ounces of beer, 5 ounces of wine, or 1.5 ounces of spirits. Those guidelines also recommend no more than 2,300 milligrams of sodium a day. The American Heart Association advocates limiting sodium to 1,500 milligrams a day.

Studies have found a significant proportion of new AFib cases are linked with drinking too much alcohol. And once an episode has been confirmed, patients have a greater chance of AFib recurring in the future.

Dr. Reimold advises people in the holiday spirit to pay attention to how much theyre drinking and eating this season. Moderation is key, she said. Another option includes the growing market of nonalcoholic beers, alcohol-free wines, mocktails, and no-alcohol spirits, from tequila to whiskey to gin.

Dr. Reimold holds the Gail Griffiths Hill Chair in Cardiology.

About UT Southwestern Medical Center

UT Southwestern, one of the nations premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty members have received six Nobel Prizes and include 26 members of the National Academy of Sciences, 21 members of the National Academy of Medicine, and 13 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 3,100 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in more than 80 specialties to more than 120,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 5 million outpatient visits a year.

Follow this link:

Drinking in moderation can help avoid 'holiday heart syndrome' - UT Southwestern

Top Cardiology Trials and Studies of 2023: Insights and Breakthroughs – Medriva

The world of cardiology continually progresses with new trials and studies, yielding vital breakthroughs and insights. In 2023, several significant cardiology trials were presented at major conferences such as the American College of Cardiologys Annual Scientific Session (#ACC23) and the American Heart Associations Scientific Sessions (#AHA23). Esteemed cardiologists @HeartBobH and @CMichaelGibson revisited these trials, providing a comprehensive review of the latest developments and research.

The American College of Cardiology highlighted several clinical topics in 2023. These included acute coronary syndromes, anticoagulation management, arrhythmias and clinical EP, atherosclerotic disease, and cardiac surgery. The ACC.org also provided related content such as guidelines, JACC journals, education and meetings, membership details, and tools and practice support. These resources offered invaluable insights into the latest findings and strategies in cardiology.

The American Journal of Managed Care provided coverage of five major topics from 2023s cardiology conferences. These included the elevated in-hospital mortality among female patients who had Acute Myocardial Infarction (AMI) and Myocardial Contusion (MC), the effective management of Heart Failure (HF) self-care post-discharge using an app, and the reduction of recurrence risk by 25% in the most common type of breast cancer by combining Ribociclib with hormonal therapy. Additionally, the importance of examining and preventing atrial fibrillation was emphasized, along with updates on efforts toward eradicating Chronic Lymphocytic Leukemia (CLL).

Various studies and clinical trials related to cardiology were featured on the JAMA Network in 2023. These encompassed a broad range of topics, from the impact of dietary interventions on blood pressure to AI explanations for biased AI models in cardiology. There was also a focus on food industry behavior, late-breaking science, and clinical highlights from the American Heart Associations Scientific Sessions meeting. Other studies compared health outcomes using different cardiac risk stratification pathways, and examined topics such as hypothermia, neprilysin inhibition, statins, medication nonadherence, and cardiovascular complications among survivors of childhood cancer.

The major cardiology trials of 2023 presented at #ACC23 and #AHA23 have shed light on numerous aspects of cardiovascular health. The valuable insights and breakthroughs gained from these trials are shaping the future of cardiology, leading to improved strategies for prevention, diagnosis, and treatment of cardiovascular diseases. As we move forward, it is crucial to continue revisiting these trials and studies to keep abreast of the latest developments in the field, ultimately enhancing patient care and outcomes in cardiology.

See the original post here:

Top Cardiology Trials and Studies of 2023: Insights and Breakthroughs - Medriva

New drugs, updated treatment strategies: 5 important trends in cardiology from an eventful 2023 – Cardiovascular Business

With the end of the year rapidly approaching, the American Heart Association (AHA) editorial staff has published a list of some of 2023s biggest breakthroughs in cardiovascular disease (CVD) research.

In 2023, investigators made important strides toward improving and extending the lives of people affected by these conditions, along with potentially lowering the burden of disease with therapies and strategies that hold promise for prevention, the AHA editors wrote. Particularly noteworthy were advances in technology to restore blood flow to blocked and narrowed arteries, potentially preventing death and disability for a wide range of patients, including those with severe illness.

The AHAs choices included:

A new investigational drug, zilebesiran, can decrease the production of angiotensinogen, a protein believed to contribute to a patient's risk of high blood pressure. Early data suggests taking zilebesiran for eight weeks is associated with reductions in key blood pressure measurements compared to a placebo; higher doses are linked to higher reductions.

Not only does the suppression of angiotensinogen hold promise for more effectively reducing hypertension for extended periods of time after injection, there is growing excitement over the possibility it also might be therapeutic for kidney and heart disease, AHAs editors wrote. The results are also highly significant because only a single dose was needed, which could improve access to care and adherence to long-term drug regimens.

The full analysis was published in The New England Journal of Medicine.[1]

The concept of using intravascular imaging to guide percutaneous coronary intervention (PCI) procedures gained significant momentum in 2023. (Cardiovascular Business wrote about this topic several times, including here, here and here.)

AHAs editors highlighted multiple studies that examined the potential impact of intravascular imaging. The ILUMIEN IV study, for example, found that PCI guided by optical coherence tomography (OCT) resulted in a larger minimum stent area than angiography-guided PCI. That analysis was published in full in The New England Journal of Medicine.[2]

The OCTIVUS trial, published in Circulation, showed that OCT-guided PCI and intravascular ultrasound were both safe and effective treatment options for patients with significant coronary artery lesions.[3]

Treating atrial fibrillation (AFib) patients with direct-acting oral anticoagulants (DOACs) after a stroke can reduce their risk of experiencing another strokebut the exact timing of prescribing those DOACs remains unclear.

Doing so too early could increase the risk of brain bleeds, while doing so later could raise the risk of having a second stroke, AHAs editors wrote.

Physicians typically recommend stroke patients wait a few days before they start taking DOACs, but new research published in The New England Journal of Medicine provided evidence that those patients could start treatment even sooner.[4]

Overall, the study found that starting DOAC treatment within 48 hours of a stroke was associated with outcomes comparable to starting treatment on day three or four after a strokeone key difference was that the risk of recurrent stroke appeared to decrease with early treatment.

The trial was not designed to test whether earlier treatment was better than later treatment, but to help health care providers estimate possible outcomes, the editors wrote.

Original post:

New drugs, updated treatment strategies: 5 important trends in cardiology from an eventful 2023 - Cardiovascular Business

Overview of Major Cardiology Trials in 2023 – Medriva

Overview of Major Cardiology Trials in 2023

With each passing year, advancements in the field of cardiology are made at an astonishing rate. The year 2023 was no different, with crucial cardiology trials and research being conducted, pushing the boundaries of our knowledge and understanding of cardiovascular health. Renowned cardiologists, Robert A. Harrington and C. Michael Gibson, reviewed these trials, shedding light on the latest developments and their potential impact on the field.

The ACC 23 held in New Orleans was a significant event that brought together cardiology experts from around the globe. One of the highlights was the CLEAR Outcomes trial. This trial showed that the addition of bempedoic acid to other therapies significantly reduced clinical events for patients who are intolerant to statins. The studys findings emphasize the importance of having alternatives and choices for lowering LDL-C levels.

Another noteworthy trial discussed by Harrington and Gibson was a phase 2 trial with an oral PCSK9 inhibitor. This study underlines the importance of exploring different methods of treating cardiovascular diseases. The PCSK9 inhibitor trial is a prime example of how alternative therapies can provide viable options for lowering LDL-C levels, thus broadening the spectrum of potential treatments.

A comprehensive review of the top cardiology trials of 2023 further underscores the importance of these trials for the future of cardiology. This includes major clinical topics highlighted by the American College of Cardiology, the top five conference coverage, and key studies and clinical trials featured on the JAMA Network. Revisiting these trials is essential as it not only provides a better understanding of the studies but also paves the way for future research and developments.

2023 saw some remarkable breakthroughs in heart disease treatment and research. These included new drug therapies, innovative medical devices, and novel treatment approaches. These advancements have the potential to revolutionize the way cardiovascular diseases are treated, offering new hope to patients worldwide. The top cardiology trials of 2023 have demonstrated that the field of cardiovascular research is continuously evolving, with each breakthrough bringing us one step closer to finding more effective treatments for heart diseases.

The top cardiology trials of 2023 have provided valuable insights into the latest advancements in the field. The trials not only showcased the potential of new and alternative therapies but also emphasized the importance of continuous research. As we move forward, these trials will undoubtedly play a crucial role in shaping the future of cardiology, providing a strong foundation for upcoming research and the development of more effective and efficient treatments for cardiovascular diseases.

Originally posted here:

Overview of Major Cardiology Trials in 2023 - Medriva

Cardiologists’ Holiday Wish: Medicare Pay Cuts Roasting on an Open Fire – TCTMD

As in Decembers past, the cardiology community is once again calling on Congress to stave off cuts to the Medicare Physician Fee Schedules that go into effect in 2024.

Annually, the US Centers for Medicare & Medicaid Services (CMS) announces its Physician Fee Schedule (PFS), and for the past several years, cardiologists have protested cuts for the care or services they provide. Some have called for an overhaul of the whole system, which often results in advocacy groups scrambling for last-minute legislation to push off proposed cuts to reimbursement. This year is no different, with an impending 3.37% cut to the Medicare PFS next year.

We have once again arrived at American clinicians annual holiday tradition: urging Congress to not allow cuts to Medicare services that exacerbate financial uncertainty for practices, further threaten patient access to care, and disproportionately impact Americas rural and senior populations, said B. Hadley Wilson, MD (Sanger Heart & Vascular Institute, Atrium Health, Charlotte, NC), president of the American College of Cardiology (ACC), in a press release. For decades we have spent December looking for a quick fix to a problem that requires significant reforms. We must seek and establish sustainable payment practices that allow clinicians to continue providing access to high-quality care. While addressing this upcoming cut is critical, it is a short-term adjustment that will not create a long-term solution. It is necessary to protect patients now while we work together on lasting reform.

The ACC, as well as other medical groups like the American Medical Association (AMA), are urging members of Congress to pass the Preserving Seniors Access to Physicians Act of 2023 (HR 6683), proposed by Congressman Greg Murphy, MD, of North Carolina. This would eliminate the planned 3.37% Medicare cuts scheduled for January 1, 2024.

Last month, a total of 54 medical societies, including the ACC, the Society for Cardiovascular Angiography & Interventions (SCAI), and the Society of Thoracic Surgeons (STS), sent a joint letter to Congress demanding the full cut be dropped.

Because physicians, unlike other providers, dont receive an automatic inflationary update within Medicare, a cut of this magnitude would be detrimental for most, especially given the current rate of inflation growth. Medicare physician payments have dropped by 26% in the last 20 years, while practice expenses have risen by 47% over the same period, according to the ACC.

Continuing down this road is unsustainable, said AMA President Jesse M. Ehrenfeld, MD, MPH (Vanderbilt University Medical Center, Nashville, TN), in an AMA press release. These cuts will be felt first and hardest in rural and underserved areas that continue to face significant healthcare access challenges.

That said, Ehrenfeld continued, as Kate McCallister famously said in Home Alone, This is Christmasthe season of perpetual hope. . . . We urge lawmakers to act quickly, preserve Medicare access, and pass this vital legislation.

Excerpt from:

Cardiologists' Holiday Wish: Medicare Pay Cuts Roasting on an Open Fire - TCTMD

Jean-Philippe Collet, Thrombosis Expert and Trialist, Dies at 59 – TCTMD

Jean-Philippe Collet, MD, PhD (Hpital de la Piti-Salptrire, Paris, France), an interventionalist and well-respected authority on antithrombotic therapies, died suddenly at home on December 15, 2023, at age 59. News of his death was confirmed by colleagues and his institution.

Well known for his leadership in co-chairing the 2020 European Society of Cardiology guidelines for non-ST-segment elevation acute coronary syndromes as well as conducting prominent research on antithromboticsincluding the ATLANTIS and ARCTIC trialsCollet will be remembered for his genuine care for patients and colleagues alike, modest yet effective demeanor, and passion for the field of cardiology.

Professor Collet was more than a colleague; he was a friend, a confidant and a role model to all those lucky enough to work alongside him, his colleague and mentor Gilles Montalescot, MD, PhD (Centre Hospitalier Universitaire Piti-Salptrire, Paris, France), wrote in an email that was circulated throughout their institution. His colleagues, his students, his patients and all those who had the chance to know him mourn the loss of an exceptional man, of rare intelligence and humanity, who devoted his life to cardiology.

To TCTMD, Montalescot reminisced about how their careers intertwined. He was my first buddy in cardiology 30 years ago and we started building this group that we have here, he said. Now it's a big group of cardiologists and a big network of cardiology centers, but we built that network together, Jean-Philippe and myself. We were the two pioneers, and one has disappeared.

Accomplished Yet Humble

Several themes emerged from Collets colleagues, who remember him for reaching unusual levels of achievement while remaining steadfastly kind and modest.

I am so devastated, P. Gabriel Steg, MD (Hpital Bichat, Paris, France), told TCTMD. He was a long-standing friend and colleague, warm, generous, hardworking, brilliant yet humble, highly respected by colleagues and staff, and loved by patients and families.

Calling Collet a friend first, Pierre Sabouret, MD (Hpital de la Piti-Salptrire, Paris, France), told TCTMD that his kindness stood out over the more than 20 years they knew each other. I want to underline that before being an international expert, he was a gentleman, he said.

Remembering Collet as both accomplished and unpretentious, Davide Capodanno, MD, PhD (University of Catania, Italy), told TCTMD that his loss will leave a gap in the field of cardiology. What really impressed me was that he was famous, but at the same time, always a person that came to you trying to have a conversation, he said. It was very easy to speak with him. And when you realize how famous he was and how friendly he was, this approach tells you how great he was as a man.

Thomas Cuisset, MD, PhD (CHU Timone, Marseille, France), too, said Collets attitude was special. Jean-Philippe was unique in the way that he made possible what many think contradictory; being one of the most famous French cardiologists, head of [his department], chair of ESC guidelines, but also a truly passionate clinician, dedicated to education, and always so friendly and supportive for the younger generation, he told TCTMD in an email. I had the privilege to work with him, and all this inspiration will stay [with me] forever.

Sunil Rao, MD (NYU Langone Medical Center, New York, NY), who also took to X (formerly Twitter) to express his condolences, called Collet "a powerful force in cardiology."

"Not only was he on the cutting edge of science, but he was also a gentleman and very approachable," Rao told TCTMD. "He will be greatly missed, but his legacy lives on in his contributions to the field, which will never be forgotten."

Eric Van Belle, MD, PhD (CHU Lille, France), a frequent research partner most recently on ATLANTIS, called Collet a trailblazer and his death a major loss. We were following his path, he said. Most of us were trying to be as good as he was, which was difficult to do. He was a very good example for all of us. He pushed us in a good direction by inspiring us.

Holger Thiele, MD (Heart Center Leipzig at University of Leipzig, Germany), who served as co-author of the 2020 ESC guidelines, told TCTMD Collet was suited to the job because he knew everything about all the evidence, in particular on antiplatelet therapy, and he was always extremely concise.

Outside of his work, Thiele added, Collet loved to be athleticthe pair would often run togetherand he enjoyed riding his motorcycle, which he would take on multiday trips to places like Rome and Barcelona for ESC Congresses.

Training and Leadership

Collet trained in cardiology at Universit Paris XII and earned his PhD in thrombosis at the University of Rouen, France. Since 2022, Collet served as head of the department of cardiology at his institution, where he also served as director of the cath lab.

John Weisel, PhD (Perelman School of Medicine, University of Pennsylvania, Philadelphia), who mentored Collet as a PhD candidate as well as a postdoctoral fellow, remembered him as very low key but enthusiastic and glad to try to do things. Weisel told TCTMD: He was probably my most productive postdoctoral fellow in the sense that I think in that 1 year he eventually got 13 papers out of the work he did.

What was unique about Collet was that he combined clinical expertise with basic science to improve patient care, Weisel continued, adding that he also really paid attention to people.

Montalescot called Collets natural leadership skills indisputable. He transformed the cardiology department into a place of excellence and innovation, where each member of the team was encouraged to reach their full potential, Montalescot continued, noting Collets charisma and ability to inspire as well as his kindness. Always approachable and modest, he was generous, attentive and loved by all his colleagues. We will always remember his kind smile, his availability and his willingness to share his knowledge.

Sabouret agreed, saying, I hope that [Collets team] will follow his model in terms of research but also in terms of attitude.

Collet was also a professor of cardiology at Sorbonne Universit and a founding and senior member of the academic research organization ACTION. His research interests were many, including finding new models for experimental thrombosis, demonstrating the prognostic role of biomarkers, and comparing antithrombotic therapies.

Throughout his career, Collet published almost 500 articles as well as 45 book chapters and 200 abstracts. One of his early works was lauded for playing an important role in the discovery of the clopidogrel resistance polymorphism.

A member of many organizations, including the French Society of Cardiology, European Society of Cardiology, Working Group 18, and European Association of Percutaneous Cardiovascular Interventions, Collet also served as an associate editor of JACC: Cardiovascular Interventions since 2018.

Collet is survived by his wife, Hlne, and their children, Antoine, Alexis, and Olivier.

Read more here:

Jean-Philippe Collet, Thrombosis Expert and Trialist, Dies at 59 - TCTMD

New vest developed by cardiologists uses advanced heart imaging to screen for sudden cardiac arrest – Cardiovascular Business

We identified a problem in cardiology, Captur said in a statement. Heart imaging has made remarkable progress in recent decades, but the electrics of the heart have eluded us. The standard technology to monitor the hearts electrical activity, the 12-lead electrocardiogram (ECG), has barely changed in 50 years. We believe the vest we have developed could be a quick and cost-effective screening tool and that the rich electrical information it provides could help us better identify peoples risk of life-threatening heart rhythms in the future.

The teams analysis includes data from 77 healthy volunteers who were imaged using the ECGI vest. The authors concluded that its use is feasible and shows good reproducibility in younger and older participants.

To date, more than 800 patients have been treated using this new screening tool. The group is currently exploring its options when it comes to the large-scale manufacturing of additional vests.

Click here to read the full analysis.

See original here:

New vest developed by cardiologists uses advanced heart imaging to screen for sudden cardiac arrest - Cardiovascular Business

Piedmont Cardiologist Starts Non-Profit to Resolve Cardiac Crisis in Ethiopia – The Citizen.com

Piedmont interventional cardiologist Tesfaye Telila, M.D., is on a mission to resolve what can be deemed a cardiac crisis in his homeland of Ethiopia. As the population in that country adopted a more western lifestyle, the incidence of heart disease has risen drastically. Knowing this epidemiologic shift and the increase in premature deaths due to heart attacks and strokes, Dr. Telila founded the nonprofit organization, Heart Attack Ethiopia, to raise the needed funds to raise awareness, and train more interventional cardiologists, in a country where only five cardiac surgeons exist for 120 million people. According to research published in ScienceDirect, more than 15,000 patients are on the waitlist for cardiac surgery in Ethiopia.

The mission of our organization is to establish a sustainable cardiovascular service line in Ethiopia, Dr. Telila said. In this first phase of our intervention, we are recruiting volunteers to provide mission-based lifesaving heart attack care at currently available institutions in Ethiopia and eventually establish a more comprehensive Cardiovascular Center of Excellence that will be operated by the local healthcare professionals and that is fully accessible to everyone in need of emergency lifesaving cardiovascular care irrespective of their socioeconomic background

Dr. Telila is also working to establish a collaborative common ground between the Ethiopian government and the State of Georgia to build and virtually integrate cardiovascular centers in Ethiopia with cardiac centers in Georgia with the aim of alleviating the critical shortage of trained cardiac professionals. Currently, the country of Ethiopia has no established primary percutaneous coronary intervention (PCI) center to provide a timely treatment for patients with heart attacks. A somewhat interrupted lifesaving cardiac care is only provided at four local centers in Addis Ababa, a city of over 7 million people. While one is a charity, patients at the other three centers must have the needed funds to pay out of pocket for their heart attack care if they are lucky to get to the center on time despite the lack of EMS services.

Cardiovascular disease remains the number one killer in the world and 75 to 80 percent of all cardiovascular deaths occur in the low and middle income countries. So, incidents that people would survive here in the U.S. are mostly fatal in Ethiopia Dr. Telila said. We can make a big impact in the world by collaborating with healthcare systems like Piedmont, medical device companies and industries, recruiting volunteers to save lives while also expanding our footprints internationally

Dr. Telila received his medical degree from Addis Ababa University in Addis Ababa, Ethiopia before moving to the U.S. where he completed his internal medicine residency and Cardiovascular fellowships. He received his fellowship in interventional and structural cardiology from the University of Wisconsin in Madison, Wisc. He is board certified in Internal Medicine, Cardiovascular Disease, Interventional Cardiology, Nuclear Cardiology and Adult Echocardiography. He now treats patients at Piedmont Fayette and Piedmont Newnan hospitals.

To learn more about cardiovascular services at Piedmont, visit piedmont.org/heart. To learn more about Heart Attack Ethiopia and how you can help, visit heartattackethiopia.org.

See original here:

Piedmont Cardiologist Starts Non-Profit to Resolve Cardiac Crisis in Ethiopia - The Citizen.com